Crotonaldehyde accumulates in glial cells of Alzheimer's disease brain

Acta Neuropathologica

Volumn 111, Issue 5, 2006, Pages 422-429

  Kawaguchi Niida, Motoko ^a   Shibata, Noriyuki ^a   Morikawa, Shunichi ^a   Uchida, Koji ^b   Yamamoto, Tomoko ^a   Sawada, Tatsuo ^a   Kobayashi, Makio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Astrocyte; Crotonaldehyde; Lipid peroxidation; Microglia

Indexed keywords

4 HYDROXYNONENAL; ACROLEIN; CROTONALDEHYDE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BRAIN REGION; CARBONYLATION; CELLULAR DISTRIBUTION; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIA CELL; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID PEROXIDATION; MALE; MICROGLIA; NEURITE; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; SENILE PLAQUE;

ACROLEIN; AGED; AGED, 80 AND OVER; ALDEHYDES; ALZHEIMER DISEASE; ASTROCYTES; BRAIN; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; NEUROGLIA; OXIDATIVE STRESS;

EID: 33646252931     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-006-0044-1     Document Type: Article

References (37)

1. Benistant C, Dehouck MP, Fruchart JC, Cecchelli R, Lagarde M (1995) Fatty acid composition of brain capillary endothelial cells: Effect of the coculture with astrocytes. J Lipid Res 36:2311-2319
2. Calingasan NY, Uchida K, Gibson GE (1999) Protein-bound acrolein: A novel marker of oxidative stress in Alzheimer's disease. J Neurochem 72:751-756
3. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 293:1566-1570
4. Dei R, Takeda A, Niwa H, Li M, Nakagomi Y, Watanabe M, Inagaki T, Washimi Y, Yasuda Y, Horie K, Miyata T, Sobue G (2002) Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol 104:113-122
5. Drake J, Link CD, Butterfield DA (2003) Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid β-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24:415-420
6. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128
7. Fontaine FR, Dunlop RA, Petersen DR, Burcham PC (2002) Oxidative bioactivation of crotyl alcohol to the toxic endogenous aldehyde crotonaldehyde: Association of protein carbonylation with toxicity in mouse hepatocytes. Chem Res Toxicol 15:1051-1058
8. Frank J, Pompella A, Biesalski HK (2000) Histochemical visualization of oxidant stress. Free Radic Biol Med 29:1096-1105
9. Furuta A, Price DL, Pardo CA, Troncoso JC, Xu ZS, Taniguchi N, Martin LJ (1995) Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 146:357-367
10. Goto Y, Okamoto S, Yonekawa Y, Taki W, Kikuchi H, Handa H, Kito M (1998) Degradation of phospholipid molecular species during experimental cerebral ischemia in rats. Stroke 19:728-735
11. Horikoshi Y, Sasaki A, Taguchi N, Maeda M, Tsukagoshi H, Sato K, Yamaguchi H (2003) Human GLUT5 immunolabeling is useful for evaluating microglial status in neuropathological study using paraffin sections. Acta Neuropathol 105:157-162
12. Ichihashi K, Osawa T, Toyokuni S, Uchida K (2001) Endogenous formation of protein adducts with carcinogenic aldehydes: Implications for oxidative stress. J Biol Chem 276:23903-23913
13. Innis SM (1991) Essential fatty acids in growth and development. Prog Lipid Res 30:39-103
14. Levine RL (2002) Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med 32:790-796
15. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18:457-461
16. Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187-194
17. Luczaj W, Skrzydlewska E (2003) DNA damage caused by lipid peroxidation products. Cell Mol Biol Lett 8:391-413
18. Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9:133-146
19. Mottaran E, Stewart SF, Rolla R, Vay D, Cipriani V, Moretti M, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E (2002) Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med 32:38-45
20. Picklo MJ, Montine TJ, Amarnath V, Neely MD (2002) Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 184:187-197
21. Markesbery WR, Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33-36
22. Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M Eisdorfer C (2002) The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 202:13-23
23. Mirra SS, Hyman BT (2002) Ageing and dementia; Alzheimer's disease. In: Graham DI, Lantos PL (ed) Greenfield's neuropathology, 7th edn, vol 2. Arnold, London, pp 200-226
24. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ (1997) 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 56:866-871
25. Nath RG, Ocando JE, Guttenplan JB, Chung FL (1998) 1, N 2 -propanodeoxyguanosine adducts: Potential new biomarkers of smoking-induced DNA damage in human oral tissue. Cancer Res 58:581-584
26. Perry G, Cash AD, Smith MA (2002) Alzheimer disease and oxidative stress. J Biomed Biotechnol 2:120-123
27. Reddy S, Finkelstein EI, Wong PSY, Phung A, Cross CE, Van der Vliet A (2002) Identification of glutathione modifications by cigarette smoke. Free Radic Biol Med 33:1490-1498
28. Sasaki A, Horikoshi Y, Yokoo H, Nakazato Y, Yamaguchi H (2003) Antiserum against human glucose transporter 5 is highly specific for microglia among cells of the mononuclear phagocyte system. Neurosci Lett 338:17-20
29. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68:2092-2097
30. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S, Kobayashi M (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917:97-104
31. Smith MA, Sayre LM, Anderson VE, Harris PLR, Beal MF, Kowall N, Perry G (1998) Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 46:731-735
32. Stadtman ER (1990) Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 9:315-325
33. Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z (2001) Immunological detection of a novel advanced glycation end-product. Mol Med 7:783-791
34. Urakami K, Sato K, Okada A, Mura T, Shimomura T, Takenaka T, Wakutani Y, Oshima T, Adachi Y, Takahashi K, Endo H (1995) Cu,Zn superoxide dismutase in patients with dementia of the Alzheimer type. Acta Neurol Scand 91:165-168
35. Van Everbroeck B, Dobbeleir I, De Waele M, De Leenheir E, Lubke U, Martin JJ, Cras P (2004) Extracellular protein deposition correlates with glial activation and oxidative stress in Creutzfeldt-Jakob and Alzheimer's disease. Acta Neuropathol 108:194-200
36. Von Tungeln LS, Yi P, Bucci TJ, Samokyszyn VM, Chou MW, Kadlubar FF, Fu PP (2002) Tumorigenicity of chloral hydrate, trichloroacetic acid, trichloroethanol, malondialdehyde, 4-hydroxy-2-nonenal, crotonaldehyde, and acrolein in the B6C3F(1) neonatal mouse. Cancer Lett 185:13-19
37. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135-142